Find a Clinical Trial

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Arizona Oncology - Glendale

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NSCLC
USOR Number: 15203

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NSCLC
USOR Number: 15203

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NSCLC
USOR Number: 15203

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, Arizona 85027
P: (602) 357-2400

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Scottsdale

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NSCLC
USOR Number: 15203

  • Practice Details

10460 N 92nd St, Suite 402
Scottsdale, Arizona 85258
P: (480) 860-2540

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Sedona

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NSCLC
USOR Number: 15203

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Glendale

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, Arizona 85027
P: (602) 357-2400

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Scottsdale

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

10460 N 92nd St, Suite 402
Scottsdale, Arizona 85258
P: (480) 860-2540

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Scottsdale

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

10197 N 92nd St, Suite 101
Scottsdale, Arizona 85258
P: (480) 993-2950

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Sedona

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Tucson

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

1845 W Orange Grove, Bldg 1
Tucson, Arizona 85704
P: (520) 544-2919

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Tucson

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Tucson

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Tucson

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: Non-Hodgkins
USOR Number: 13092

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Melanoma

Clinical Trial at: Arizona Oncology - Glendale

A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

  • Details

ClinicalTrials.gov ID: NCT03273153
Diagnosis Type: NA
USOR Number: 17013

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Melanoma

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

  • Details

ClinicalTrials.gov ID: NCT03273153
Diagnosis Type: NA
USOR Number: 17013

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Pages